TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Karl Deisseroth, Peter Hegemann and Georg Nagel were awarded the Nobel Prize in Physiology or Medicine for research that enabled optogenetics, a method for using light to control nerve cells. The technique is used mainly in research to study brain circuits; its role in future treatments remains under investigation.
The Nobel Prize in Physiology or Medicine was awarded Monday to Karl Deisseroth, Peter Hegemann and Georg Nagel for research that enabled optogenetics, a method using light to switch nerve cells on or off. The Nobel Assembly said the tool is now used in laboratories worldwide to investigate how the brain works, including how neural circuits relate to behavior and disease.
The work combined discoveries about light-sensitive ion channels with methods for using them to control neurons. Hegemann studied how single-celled green algae move toward light. He and Nagel identified a protein that opens a channel when illuminated with blue light, producing an electrical impulse. Introducing the gene for that protein into other cells can make those cells responsive to light.
Deisseroth then used the gene to create a way to control nerve cells in the brains of living mice. He developed tiny optical fibers to deliver light to modified cells, allowing researchers to activate or inhibit selected neurons and circuits. The method gives researchers a way to test what particular cells do rather than only observe their activity.
Optogenetics remains primarily a research technique, Deisseroth said in the report. Other scientists are pursuing possible treatment applications, including approaches related to autism and schizophrenia. A form he called direct optogenetics is being used to test a treatment for retinitis pigmentosa, a genetic cause of vision loss; the report does not provide trial results or establish that the approach is an approved treatment.
How Light Became a Neuroscience Tool
The award recognizes a method that lets researchers manipulate specific neural activity with precision in time and location. By switching selected cells on or off, researchers can investigate whether a circuit contributes to a behavior or a disease process, questions that can be difficult to answer through observation alone.
The technique has also helped scientists examine disrupted brain circuits, according to Nobel Assembly member Abdel El Manira, with potential relevance to conditions including blindness, depression, addiction and dementia. That research contribution should not be confused with proof of a clinical benefit: the supplied report describes optogenetics mainly as a laboratory tool and says treatment applications are being pursued or tested.
University of Pittsburgh researcher Jeremy Berg, who was at the National Institutes of Health when Deisseroth received early major funding, described optogenetics as a precise set of tools for experiments that would otherwise be hard to conduct. The distinction matters to readers: the prize honors foundational research, while any future medical use requires further study.
As an affiliate, we earn on qualifying purchases.
From Algae to Living-Mouse Neurons
The discovery began with a question about how green algae sense light. Hegemann’s research, followed by work with Nagel, identified a light-controlled protein channel. The key step toward optogenetics came when researchers used the gene for that protein in other cells, making it possible to affect electrical activity with light.
Deisseroth’s group adapted that principle for neuroscience by delivering light to genetically modified nerve cells in living mice. The Nobel Assembly described the resulting technique as opening a new era in neuroscience. The report says laboratories around the world now use it to examine brain activity and circuit function.
The award was announced at the Karolinska Institute in Stockholm and opened the week’s Nobel announcements. The prize amount reported was 12 million Swedish kronor, about $1.2 million, shared among the laureates. The report says the three scientists are affiliated with Stanford University and the Howard Hughes Medical Institute, Humboldt University in Berlin, and the University of Würzburg, respectively.
“People usually think about light as a way of collecting information to observe things. But this is the opposite of that. This is using light to control things, to make things happen, and to do it in a very precise way.”
— Karl Deisseroth, as quoted by MedPage Today
light-controlled neuron stimulation kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Clinical Uses Remain Under Study
The award recognizes research enabling optogenetics; it does not establish that the method can treat the conditions cited by the Nobel Assembly. The report does not specify the stage, size or outcomes of the retinitis pigmentosa treatment test, nor does it give details about the proposed approaches for autism or schizophrenia.
It is also unclear from the report how broadly direct optogenetics can be applied in people, or what practical and safety limits may shape clinical use. Deisseroth said other techniques for switching neurons on or off are being studied, but the article gives no further details. The long-term clinical impact remains unsettled.
neuroscience laboratory light source
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Nobel Week and Further Research
The report said Nobel announcements would continue with the physics prize on Tuesday, chemistry on Wednesday and literature on Thursday, followed by the peace prize on Friday and the economics prize on Oct. 12. Thomas Perlmann, secretary of the medicine committee, said he had reached all three laureates on Monday.
For optogenetics, the next developments will come through neuroscience studies and the treatment research described by Deisseroth. The supplied report gives no timetable for clinical results or regulatory decisions, so any medical application remains a subject for further research rather than an established consequence of the prize.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who won the Nobel Prize in Physiology or Medicine?
Karl Deisseroth, Peter Hegemann and Georg Nagel received the prize for research that enabled optogenetics.
What is optogenetics?
Optogenetics uses light-sensitive proteins and light delivery to activate or inhibit selected cells. In neuroscience, researchers use it to control specific nerve cells and circuits and study their function.
Does the prize mean optogenetics is an established treatment?
No. The report describes optogenetics mainly as a research method. Some treatment applications are being pursued or tested, but the report provides no evidence that these uses are established treatments.
What discovery helped make optogenetics possible?
Hegemann and Nagel identified a protein in algae that responds to blue light by opening a channel and producing an electrical impulse. Researchers later used the gene for that protein to make other cells responsive to light.
How much prize money was reported?
The report gives the prize amount as 12 million Swedish kronor, approximately $1.2 million, shared by the laureates.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
